These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8993501)

  • 21. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme.
    Pommier Y; Pourquier P; Fan Y; Strumberg D
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):83-105. PubMed ID: 9748515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug resistance mechanisms of topoisomerase I drugs.
    Andoh T; Okada K
    Adv Pharmacol; 1994; 29B():93-103. PubMed ID: 8996603
    [No Abstract]   [Full Text] [Related]  

  • 23. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
    Furukawa M; Harada T; Tanaka T; Kuwano M
    Nihon Rinsho; 1997 May; 55(5):1096-102. PubMed ID: 9155159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The topoisomerase-related function gene TRF4 affects cellular sensitivity to the antitumor agent camptothecin.
    Walowsky C; Fitzhugh DJ; Castaño IB; Ju JY; Levin NA; Christman MF
    J Biol Chem; 1999 Mar; 274(11):7302-8. PubMed ID: 10066793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and cytotoxic activity of new 9-substituted camptothecins.
    Dallavalle S; Rocchetta DG; Musso L; Merlini L; Morini G; Penco S; Tinelli S; Beretta GL; Zunino F
    Bioorg Med Chem Lett; 2008 May; 18(9):2781-7. PubMed ID: 18434153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of camptothecin on topoisomerase I catalysis.
    Christiansen K; Westergaard O
    Ann N Y Acad Sci; 1996 Dec; 803():50-9. PubMed ID: 8993500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA strand-breaks induced by the topoisomerase I inhibitor camptothecin in unstimulated human white blood cells.
    Daza P; Torreblanca J; García-Herdugo G; Moreno FJ
    Cell Biol Int; 2002; 26(8):707-13. PubMed ID: 12175674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Camptothecins as probes of the microenvironments of topoisomerase I--DNA complexes.
    Hecht SM
    Ann N Y Acad Sci; 2000; 922():76-91. PubMed ID: 11193927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH; Andersson BS; Nelson JA
    Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity.
    Morris EJ; Geller HM
    J Cell Biol; 1996 Aug; 134(3):757-70. PubMed ID: 8707853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance.
    Losasso C; Cretaio E; Fiorani P; D'Annessa I; Chillemi G; Benedetti P
    Nucleic Acids Res; 2008 Oct; 36(17):5635-44. PubMed ID: 18772225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.
    Perego P; Cossa G; Tinelli S; Corna E; Carenini N; Gatti L; De Cesare M; Ciusani E; Zunino F; Luison E; Canevari S; Zaffaroni N; Beretta GL
    Biochem Pharmacol; 2012 Jan; 83(1):27-36. PubMed ID: 21978643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.
    Desai SD; Zhang H; Rodriguez-Bauman A; Yang JM; Wu X; Gounder MK; Rubin EH; Liu LF
    Mol Cell Biol; 2003 Apr; 23(7):2341-50. PubMed ID: 12640119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Luotonin A. A naturally occurring human DNA topoisomerase I poison.
    Cagir A; Jones SH; Gao R; Eisenhauer BM; Hecht SM
    J Am Chem Soc; 2003 Nov; 125(45):13628-9. PubMed ID: 14599178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New analogues of camptothecins. Activity and resistance.
    Boven E; Van Hattum AH; Hoogsteen I; Schlüper HM; Pinedo HM
    Ann N Y Acad Sci; 2000; 922():175-7. PubMed ID: 11193892
    [No Abstract]   [Full Text] [Related]  

  • 38. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
    Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
    Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 and p21 are major cellular determinants for DNA topoisomerase I-mediated radiation sensitization in mammalian cells.
    Chen AY; Scruggs PB; Geng L; Rothenberg ML; Hallahan DE
    Ann N Y Acad Sci; 2000; 922():298-300. PubMed ID: 11193905
    [No Abstract]   [Full Text] [Related]  

  • 40. DNA topoisomerase I-targeting drugs as radiation sensitizers.
    Chen AY; Choy H; Rothenberg ML
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.